Inicio
Detalle del título uniforme
Annals of the Rheumatic Diseases
Tipo de obra :
Autre
Naturaleza de la obra :
Oeuvre
|
Documentos disponibles con este título uniforme (2)
Clasificado(s) por (Año de edición descendente) Refinar búsqueda
First Latin American clinical practice guidelines for the treatment of systemic lupus erythematosus: Latin American Group for the Study of Lupus (GLADEL, Grupo Latino Americano de Estudio del Lupus)–Pan-American League of Associations of Rheumatology (PANLAR) / Ruth María Eraso Garnica
Título : First Latin American clinical practice guidelines for the treatment of systemic lupus erythematosus: Latin American Group for the Study of Lupus (GLADEL, Grupo Latino Americano de Estudio del Lupus)–Pan-American League of Associations of Rheumatology (PANLAR) Tipo de documento : documento electrónico Autores : Ruth María Eraso Garnica, Fecha de publicación : 2018 Títulos uniformes : Annals of the Rheumatic Diseases Idioma : Inglés (eng) Palabras clave : Lupus nephritis systemic lupus erythematosus treatment Resumen : Systemic lupus erythematosus (SLE), a complex and heterogeneous autoimmune disease, represents a significant challenge for both diagnosis and treatment. Patients with SLE in Latin America face special problems that should be considered when therapeutic guidelines are developed. The objective of the study is to develop clinical practice guidelines for Latin American patients with lupus. Two independent teams (rheumatologists with experience in lupus management and methodologists) had an initial meeting in Panama City, Panama, in April 2016. They selected a list of questions for the clinical problems most commonly seen in Latin American patients with SLE. These were addressed with the best available evidence and summarised in a standardised format following the Grading of Recommendations Assessment, Development and Evaluation approach. All preliminary findings were discussed in a second face-to-face meeting in Washington, DC, in November 2016. As a result, nine organ/system sections are presented with the main findings; an 'overarching' treatment approach was added. Special emphasis was made on regional implementation issues. Best pharmacologic options were examined for musculoskeletal, mucocutaneous, kidney, cardiac, pulmonary, neuropsychiatric, haematological manifestations and the antiphospholipid syndrome. The roles of main therapeutic options (ie, glucocorticoids, antimalarials, immunosuppressant agents, therapeutic plasma exchange, belimumab, rituximab, abatacept, low-dose aspirin and anticoagulants) were summarised in each section. In all cases, benefits and harms, certainty of the evidence, values and preferences, feasibility, acceptability and equity issues were considered to produce a recommendation with special focus on ethnic and socioeconomic aspects. Guidelines for Latin American patients with lupus have been developed and could be used in similar settings. Mención de responsabilidad : Bernardo A Pons-Estel, Eloisa Bonfa, Enrique R Soriano, Mario H Cardiel, Ariel Izcovich, Federico Popoff, Juan M Criniti, Gloria Vásquez, Loreto Massardo, Margarita Duarte, Leonor A Barile-Fabris, Mercedes A García, Mary-Carmen Amigo, Graciela Espada, Luis J Catoggio, Emilia Inoue Sato, Roger A Levy, Eduardo M Acevedo Vásquez, Rosa Chacón-Díaz, Claudio M Galarza-Maldonado, Antonio J Iglesias Gamarra, José Fernando Molina, Oscar Neira, Clóvis A Silva, Andrea Vargas Peña, José A Gómez-Puerta, Marina Scolnik, Guillermo J Pons-Estel, Michelle R Ugolini-Lopes, Verónica Savio, Cristina Drenkard, Alejandro J Alvarellos, Manuel F Ugarte-Gil, Alejandra Babini, André Cavalcanti, Fernanda Athayde Cardoso Linhares, Maria Jezabel Haye Salinas, Yurilis J Fuentes-Silva, Ana Carolina Montandon de Oliveira E Silva, Ruth M Eraso Garnica, Sebastián Herrera Uribe, Diana Gómez-Martín, Ricardo Robaina Sevrini, Rosana M Quintana, Sergio Gordon, Hilda Fragoso-Loyo, Violeta Rosario, Verónica Saurit, Simone App Referencia : Ann Rheum Dis. 2018 Nov;77(11):1549-1557. DOI (Digital Object Identifier) : 10.1136/annrheumdis-2018-213512 PMID : 30045853 En línea : https://ard.bmj.com/content/77/11/1549 Enlace permanente : https://hospitalpablotobon.cloudbiteca.com/pmb/opac_css/index.php?lvl=notice_display&id=4178 First Latin American clinical practice guidelines for the treatment of systemic lupus erythematosus: Latin American Group for the Study of Lupus (GLADEL, Grupo Latino Americano de Estudio del Lupus)–Pan-American League of Associations of Rheumatology (PANLAR) [documento electrónico] / Ruth María Eraso Garnica, . - 2018.
Obra : Annals of the Rheumatic Diseases
Idioma : Inglés (eng)
Palabras clave : Lupus nephritis systemic lupus erythematosus treatment Resumen : Systemic lupus erythematosus (SLE), a complex and heterogeneous autoimmune disease, represents a significant challenge for both diagnosis and treatment. Patients with SLE in Latin America face special problems that should be considered when therapeutic guidelines are developed. The objective of the study is to develop clinical practice guidelines for Latin American patients with lupus. Two independent teams (rheumatologists with experience in lupus management and methodologists) had an initial meeting in Panama City, Panama, in April 2016. They selected a list of questions for the clinical problems most commonly seen in Latin American patients with SLE. These were addressed with the best available evidence and summarised in a standardised format following the Grading of Recommendations Assessment, Development and Evaluation approach. All preliminary findings were discussed in a second face-to-face meeting in Washington, DC, in November 2016. As a result, nine organ/system sections are presented with the main findings; an 'overarching' treatment approach was added. Special emphasis was made on regional implementation issues. Best pharmacologic options were examined for musculoskeletal, mucocutaneous, kidney, cardiac, pulmonary, neuropsychiatric, haematological manifestations and the antiphospholipid syndrome. The roles of main therapeutic options (ie, glucocorticoids, antimalarials, immunosuppressant agents, therapeutic plasma exchange, belimumab, rituximab, abatacept, low-dose aspirin and anticoagulants) were summarised in each section. In all cases, benefits and harms, certainty of the evidence, values and preferences, feasibility, acceptability and equity issues were considered to produce a recommendation with special focus on ethnic and socioeconomic aspects. Guidelines for Latin American patients with lupus have been developed and could be used in similar settings. Mención de responsabilidad : Bernardo A Pons-Estel, Eloisa Bonfa, Enrique R Soriano, Mario H Cardiel, Ariel Izcovich, Federico Popoff, Juan M Criniti, Gloria Vásquez, Loreto Massardo, Margarita Duarte, Leonor A Barile-Fabris, Mercedes A García, Mary-Carmen Amigo, Graciela Espada, Luis J Catoggio, Emilia Inoue Sato, Roger A Levy, Eduardo M Acevedo Vásquez, Rosa Chacón-Díaz, Claudio M Galarza-Maldonado, Antonio J Iglesias Gamarra, José Fernando Molina, Oscar Neira, Clóvis A Silva, Andrea Vargas Peña, José A Gómez-Puerta, Marina Scolnik, Guillermo J Pons-Estel, Michelle R Ugolini-Lopes, Verónica Savio, Cristina Drenkard, Alejandro J Alvarellos, Manuel F Ugarte-Gil, Alejandra Babini, André Cavalcanti, Fernanda Athayde Cardoso Linhares, Maria Jezabel Haye Salinas, Yurilis J Fuentes-Silva, Ana Carolina Montandon de Oliveira E Silva, Ruth M Eraso Garnica, Sebastián Herrera Uribe, Diana Gómez-Martín, Ricardo Robaina Sevrini, Rosana M Quintana, Sergio Gordon, Hilda Fragoso-Loyo, Violeta Rosario, Verónica Saurit, Simone App Referencia : Ann Rheum Dis. 2018 Nov;77(11):1549-1557. DOI (Digital Object Identifier) : 10.1136/annrheumdis-2018-213512 PMID : 30045853 En línea : https://ard.bmj.com/content/77/11/1549 Enlace permanente : https://hospitalpablotobon.cloudbiteca.com/pmb/opac_css/index.php?lvl=notice_display&id=4178 Reserva
Reservar este documentoEjemplares(1)
Código de barras Número de Ubicación Tipo de medio Ubicación Sección Estado DD000792 AC-2018-079 Archivo digital Producción Científica Artículos científicos Disponible TAP1 and TAP2 polymorphisms analysis in northwestern Colombian patients with systemic lupus erythematosus / José Fernando Molina Restrepo
Título : TAP1 and TAP2 polymorphisms analysis in northwestern Colombian patients with systemic lupus erythematosus Tipo de documento : documento electrónico Autores : José Fernando Molina Restrepo, Fecha de publicación : 2003 Títulos uniformes : Annals of the Rheumatic Diseases Idioma : Inglés (eng) Resumen : Objective: To determine the influence of TAP1 and TAP2 alleles in northwestern Colombian patients with systemic lupus erythematosus (SLE). Methods: Unselected patients with SLE (n=140) and controls (n=120) matched for sex, age, and ethnicity were analysed. Clinical manifestations, clinical activity, and severity of disease were recorded. Autoantibodies were detected by enzyme linked immunosorbent assay (ELISA). TAP1 and TAP2 polymorphisms were determined by amplification refractory mutation system-polymerase chain reaction. A Hardy-Weinberg equilibrium test, microdifferentiation analysis, linkage disequilibrium analysis, and haplotype and allele frequency comparisons were performed. Results: The TAP2 variant Val379/Ala565/Ala665 (allele TAP2*0201) was associated with SLE (56% v 39%; odds ratio=2, 95% confidence interval 1.22 to 3.30, pc=0.03). There was no stratification between patient and control samples. Linkage disequilibrium between TAP1 and TAP2 loci was found in controls but not in patients. An excess in the number of heterozygotes in the TAP2 locus was found in patients. No association between TAP1 and TAP2 variants and the presence of autoantibodies, clinical expression, or severity of disease was found. Conclusions: The TAP2 locus influences susceptibility to SLE in our patient group; however, it has no significant effect on the immune response or on the clinical course of the disease. Mención de responsabilidad : P A Correa, J F Molina, L F Pinto, M Arcos-Burgos, M Herrera, J-M Anaya Referencia : Ann Rheum Dis. 2003 Apr;62(4):363-5. DOI (Digital Object Identifier) : 10.1136/ard.62.4.363 PMID : 12634240 En línea : https://ard.bmj.com/content/62/4/363 Enlace permanente : https://hospitalpablotobon.cloudbiteca.com/pmb/opac_css/index.php?lvl=notice_display&id=4397 TAP1 and TAP2 polymorphisms analysis in northwestern Colombian patients with systemic lupus erythematosus [documento electrónico] / José Fernando Molina Restrepo, . - 2003.
Obra : Annals of the Rheumatic Diseases
Idioma : Inglés (eng)
Resumen : Objective: To determine the influence of TAP1 and TAP2 alleles in northwestern Colombian patients with systemic lupus erythematosus (SLE). Methods: Unselected patients with SLE (n=140) and controls (n=120) matched for sex, age, and ethnicity were analysed. Clinical manifestations, clinical activity, and severity of disease were recorded. Autoantibodies were detected by enzyme linked immunosorbent assay (ELISA). TAP1 and TAP2 polymorphisms were determined by amplification refractory mutation system-polymerase chain reaction. A Hardy-Weinberg equilibrium test, microdifferentiation analysis, linkage disequilibrium analysis, and haplotype and allele frequency comparisons were performed. Results: The TAP2 variant Val379/Ala565/Ala665 (allele TAP2*0201) was associated with SLE (56% v 39%; odds ratio=2, 95% confidence interval 1.22 to 3.30, pc=0.03). There was no stratification between patient and control samples. Linkage disequilibrium between TAP1 and TAP2 loci was found in controls but not in patients. An excess in the number of heterozygotes in the TAP2 locus was found in patients. No association between TAP1 and TAP2 variants and the presence of autoantibodies, clinical expression, or severity of disease was found. Conclusions: The TAP2 locus influences susceptibility to SLE in our patient group; however, it has no significant effect on the immune response or on the clinical course of the disease. Mención de responsabilidad : P A Correa, J F Molina, L F Pinto, M Arcos-Burgos, M Herrera, J-M Anaya Referencia : Ann Rheum Dis. 2003 Apr;62(4):363-5. DOI (Digital Object Identifier) : 10.1136/ard.62.4.363 PMID : 12634240 En línea : https://ard.bmj.com/content/62/4/363 Enlace permanente : https://hospitalpablotobon.cloudbiteca.com/pmb/opac_css/index.php?lvl=notice_display&id=4397 Reserva
Reservar este documentoEjemplares(1)
Código de barras Número de Ubicación Tipo de medio Ubicación Sección Estado DD000897 AC-2003-004 Archivo digital Producción Científica Artículos científicos Disponible